Anorexia Nervosa Treatment Market By Type of Treatment (Psychological Therapy, Pharmacologic Therapy, and Others); By Applications (Hospitals, Clinics, Homecare, and Others); By Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) - Global Market Analysis, Trends, Opportunity and Forecast, 2022-2032

Anorexia Nervosa Treatment Market Size and Overview

The anorexia nervosa treatment market size is poised to reach USD 7.5 billion by the end of 2032, growing at a CAGR of 6.5% during the forecast period, i.e., 2023 – 2032. In the year 2022, the industry size of anorexia nervosa treatment market was USD 4.0 billion. The reason behind the growth can be attributed to the increased prevalence of dietary health disorders, together with anorexia nervosa, rising awareness and improved healthcare education concerning consuming issues, Advancements in medical research and the development of innovative remedy techniques and implementation of government regulations to address mental capability. The marketplace incorporates a wide range of treatment types. The market is highly competitive with key players striving to meet evolving customer demands.

Anorexia Nervosa Treatment Market Segmentation:

Type of Treatment:

• Psychological Therapy
• Pharmacologic Therapy
• Others

Applications:

• Hospitals
• Clinics
• Homecare
• Others

Geographic Regions:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

On the basis of applications in the anorexia nervosa treatment market the hospitals segment accounted the highest market share in 2022. The applications segment contains hospitals, clinics, homecare settings, and others. Among these, the hospitals segment is expected to witness rapid surge throughout the forecast period. Hospital remedy for eating disorders gives additional help and structure, making sure patients receive suitable medical care and continuous tracking. It proves to be beneficial in handling challenging situations related to anorexia nervosa, encouraging better outcomes and recovery for patients.

Anorexia Nervosa Treatment Market Regional Analysis:

North America stands as one of the major markets for anorexia nervosa treatment, driven through the growth potential for anorexia nervosa treatment. Additionally, region's unhealthy lifestyle prevalent among a substantial population make contributions to the region’s dominance. The United States, primarily, is a key contributor on this marketplace.

Europe is one of the leading marketplaces for anorexia nervosa treatment because of the region’s growing awareness of anorexia nervosa. The European market showcases a increasing availability of treatment options

The Asia Pacific anorexia nervosa treatment market is estimated to witness significant growth, during the forecast timeframe led by, rising prevalence of anorexia nervosa. The demand for anorexia nervosa treatment is anticipated to rise in countries like China and India, with increasing affluence of the population.

Latin America and the Middle East and Africa display steady growth inside the anorexia nervosa treatment market, fueled via increasing awareness of anorexia nervosa and the growing demand for treatment options, rising prevalence of anorexia nervosa in these regions. Key participants to the market's growth in these areas encompass Brazil, Mexico, the United Arab Emirates, and South Africa.

Anorexia Nervosa Treatment Market Growth Drivers:

There has been an increased prevalence of dietary health disorders, together with anorexia nervosa, which has led to an extra demand for effective treatment options. As more people are searching for help for his or her eating conduct patterns, the marketplace for anorexia nervosa remedy is predicted to enjoy extensive growth.

The rising awareness and improved healthcare education concerning consuming issues have contributed to early analysis and intervention. Healthcare experts, as well as the overall public, are actually more ready to understand the signs and symptoms of anorexia nervosa, leading to extended treatment-looking for conduct and a fine impact on marketplace boom.

Advancements in medical research and the development of innovative remedy techniques have progressed patient consequences and restoration fees. New healing modalities, which includes stronger cognitive-behavioral therapy (CBT-E), have shown promising consequences in treating anorexia nervosa and promoting sustained remission. Additionally, the integration of technology, consisting of virtual reality remedy and cell health applications, offers novel ways to beautify treatment efficacy and affected individual engagement.

The implementation of government regulations to address mental capability issues and eating issues has performed a substantial function in driving market surge. As governments recognition on improving mental fitness offerings and supplying aid for individuals with anorexia nervosa, get admission to medication and care is anticipated to enhance.

Anorexia Nervosa Treatment Market Challenges

Stigma surrounding mental health conditions and limited research and development are hindering the growth of market. In developing regions, this factor has resulted in limited demand for product. Moreover, the high cost of treatment is also restricting the growth of market.

Anorexia Nervosa Treatment Market Key Companies:

The anorexia nervosa treatment market is poised by several main corporations, each making big contributions to the industry through their sturdy market presence and progressive product offerings. Among these principal players are AstraZeneca, Pfizer, Timberline Knolls, EDH, NEDC, Eating Disorders Victoria, and National Association of Anorexia Nervosa among other players. These essential players constantly try and revamp their marketplace percentage and meet the desires of a diverse investor base. Their competitive techniques encompass product innovation, forging strategic partnerships, undertaking mergers and acquisitions, and increasing their distribution networks.

In April 2022, AstraZeneca announced that it had initiated a Phase 2 clinical trial of its drug, PF-07258669, for the treatment of anorexia nervosa. PF-07258669 is a selective serotonin 2C (5-HT2C) receptor antagonist that is being developed as a potential treatment for anorexia nervosa.